Claims-based feasibility analysis for Amgen's Phase 3 primary prevention trial (NCT07136012) · Data: Komodo Healthcare Map + CDC SVI + ClinicalTrials.gov
Key Finding: Lp(a) Testing Gap
Eligible Patients by Region
Competitive Exposure Summary
Stepwise attrition from Komodo Healthcare Map base population to final eligible cohort
Exclusion Impact (patients removed at each step)
Eligible patient density by state with trial site overlay
Top 25 States: Eligible Patients vs Trial Sites
States with Eligible Patients but ZERO Trial Sites
These represent geographic gaps where eligible patients have no nearby site
189 U.S. trial sites enriched with SVI vulnerability data and competitive landscape
Top providers by eligible patient volume with Lp(a) testing behavior
Top Lp(a) Testers — High-Value Investigator Targets
Eligible cohort demographics with site footprint SVI analysis
Race/Ethnicity Distribution
Site Footprint SVI Analysis
Social vulnerability distribution of the 189 trial site locations
Active Lp(a)-targeting trials with site overlap analysis
Sites with Highest Competitive Exposure
Inclusion/exclusion criteria translated from the study enrollment summary into claims-based logic